ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
FRA:ZEG - Deutsche Boerse Ag - GB0009895292 - Common Stock - Currency: EUR
Taking everything into account, ZEG scores 5 out of 10 in our fundamental rating. ZEG was compared to 50 industry peers in the Pharmaceuticals industry. ZEG scores excellent on profitability, but there are some minor concerns on its financial health. ZEG has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
ZEG had positive earnings in the past year.
ZEG had a positive operating cash flow in the past year.
In the past 5 years ZEG has always been profitable.
Each year in the past 5 years ZEG had a positive operating cash flow.
1.2 Ratios
ZEG's Return On Assets of 7.31% is fine compared to the rest of the industry. ZEG outperforms 62.00% of its industry peers.
The Return On Equity of ZEG (18.94%) is better than 68.00% of its industry peers.
With a decent Return On Invested Capital value of 14.10%, ZEG is doing good in the industry, outperforming 80.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ZEG is below the industry average of 14.75%.
The 3 year average ROIC (11.62%) for ZEG is below the current ROIC(14.10%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.31% | ||
| ROE | 18.94% | ||
| ROIC | 14.1% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
Looking at the Profit Margin, with a value of 14.14%, ZEG is in the better half of the industry, outperforming 66.00% of the companies in the same industry.
In the last couple of years the Profit Margin of ZEG has grown nicely.
ZEG's Operating Margin of 24.05% is fine compared to the rest of the industry. ZEG outperforms 66.00% of its industry peers.
In the last couple of years the Operating Margin of ZEG has grown nicely.
The Gross Margin of ZEG (82.36%) is better than 82.00% of its industry peers.
ZEG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.05% | ||
| PM (TTM) | 14.14% | ||
| GM | 82.36% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
ZEG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
ZEG has about the same amout of shares outstanding than it did 1 year ago.
ZEG has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ZEG has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.00 indicates that ZEG is not in any danger for bankruptcy at the moment.
ZEG's Altman-Z score of 5.00 is fine compared to the rest of the industry. ZEG outperforms 80.00% of its industry peers.
ZEG has a debt to FCF ratio of 3.46. This is a good value and a sign of high solvency as ZEG would need 3.46 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 3.46, ZEG is doing good in the industry, outperforming 62.00% of the companies in the same industry.
ZEG has a Debt/Equity ratio of 0.71. This is a neutral value indicating ZEG is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.71, ZEG perfoms like the industry average, outperforming 44.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 3.46 | ||
| Altman-Z | 5 |
ROIC/WACC1.59
WACC8.84%
2.3 Liquidity
ZEG has a Current Ratio of 0.90. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
ZEG has a Current ratio of 0.90. This is in the lower half of the industry: ZEG underperforms 76.00% of its industry peers.
A Quick Ratio of 0.70 indicates that ZEG may have some problems paying its short term obligations.
ZEG has a worse Quick ratio (0.70) than 74.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
ZEG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.91%, which is quite good.
ZEG shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.59% yearly.
Looking at the last year, ZEG shows a quite strong growth in Revenue. The Revenue has grown by 15.48% in the last year.
Measured over the past years, ZEG shows a quite strong growth in Revenue. The Revenue has been growing by 17.27% on average per year.
EPS 1Y (TTM)16.91%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%20.87%
Revenue 1Y (TTM)15.48%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%7.17%
3.2 Future
Based on estimates for the next years, ZEG will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.35% on average per year.
The Revenue is expected to grow by 6.34% on average over the next years.
EPS Next Y12.48%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
EPS Next 5Y11.35%
Revenue Next Year8.37%
Revenue Next 2Y7.23%
Revenue Next 3Y6.74%
Revenue Next 5Y6.34%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 16.39, the valuation of ZEG can be described as correct.
Compared to the rest of the industry, the Price/Earnings ratio of ZEG is on the same level as its industry peers.
ZEG is valuated rather cheaply when we compare the Price/Earnings ratio to 27.45, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 13.52, which indicates a correct valuation of ZEG.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ZEG indicates a somewhat cheap valuation: ZEG is cheaper than 66.00% of the companies listed in the same industry.
ZEG's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.90.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.39 | ||
| Fwd PE | 13.52 |
4.2 Price Multiples
66.00% of the companies in the same industry are cheaper than ZEG, based on the Enterprise Value to EBITDA ratio.
The rest of the industry has a similar Price/Free Cash Flow ratio as ZEG.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 48.03 | ||
| EV/EBITDA | 23.25 |
4.3 Compensation for Growth
ZEG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ZEG may justify a higher PE ratio.
PEG (NY)1.31
PEG (5Y)0.88
EPS Next 2Y12.94%
EPS Next 3Y11.87%
5. Dividend
5.1 Amount
ZEG has a Yearly Dividend Yield of 2.41%.
Compared to an average industry Dividend Yield of 3.04, ZEG pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.38, ZEG has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.41% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
ZEG pays out 63.60% of its income as dividend. This is not a sustainable payout ratio.
The dividend of ZEG is growing, but earnings are growing more, so the dividend growth is sustainable.
DP63.6%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
FRA:ZEG (7/4/2025, 7:00:00 PM)
120.3
+1.75 (+1.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners46.88%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap372.98B
Analysts82.86
Price Target158.42 (31.69%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.41% |
Yearly Dividend2.54
Dividend Growth(5Y)1.4%
DP63.6%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.34%
Min EPS beat(2)-0.63%
Max EPS beat(2)9.32%
EPS beat(4)2
Avg EPS beat(4)1.86%
Min EPS beat(4)-1.9%
Max EPS beat(4)9.32%
EPS beat(8)5
Avg EPS beat(8)2.24%
EPS beat(12)9
Avg EPS beat(12)3.68%
EPS beat(16)11
Avg EPS beat(16)2.44%
Revenue beat(2)1
Avg Revenue beat(2)-0.64%
Min Revenue beat(2)-3.99%
Max Revenue beat(2)2.7%
Revenue beat(4)2
Avg Revenue beat(4)-0.21%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)4
Avg Revenue beat(12)-0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.72%
PT rev (1m)-3.08%
PT rev (3m)-6.75%
EPS NQ rev (1m)-0.1%
EPS NQ rev (3m)-0.61%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.16%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)0.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.39 | ||
| Fwd PE | 13.52 | ||
| P/S | 7.98 | ||
| P/FCF | 48.03 | ||
| P/OCF | 33.53 | ||
| P/B | 10.69 | ||
| P/tB | N/A | ||
| EV/EBITDA | 23.25 |
EPS(TTM)7.34
EY6.1%
EPS(NY)8.9
Fwd EY7.4%
FCF(TTM)2.5
FCFY2.08%
OCF(TTM)3.59
OCFY2.98%
SpS15.07
BVpS11.25
TBVpS-4.84
PEG (NY)1.31
PEG (5Y)0.88
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.31% | ||
| ROE | 18.94% | ||
| ROCE | 17.15% | ||
| ROIC | 14.1% | ||
| ROICexc | 15.14% | ||
| ROICexgc | 76.66% | ||
| OM | 24.05% | ||
| PM (TTM) | 14.14% | ||
| GM | 82.36% | ||
| FCFM | 16.62% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexcg growth 3Y43.28%
ROICexcg growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score9
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 3.46 | ||
| Debt/EBITDA | 1.47 | ||
| Cap/Depr | 58.81% | ||
| Cap/Sales | 7.18% | ||
| Interest Coverage | 9.49 | ||
| Cash Conversion | 65.63% | ||
| Profit Quality | 117.58% | ||
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | 5 |
F-Score9
WACC8.84%
ROIC/WACC1.59
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)16.91%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%20.87%
EPS Next Y12.48%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
EPS Next 5Y11.35%
Revenue 1Y (TTM)15.48%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%7.17%
Revenue Next Year8.37%
Revenue Next 2Y7.23%
Revenue Next 3Y6.74%
Revenue Next 5Y6.34%
EBIT growth 1Y42.22%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.44%
EBIT Next 3Y17.32%
EBIT Next 5Y14.19%
FCF growth 1Y51.52%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y34.8%
OCF growth 3Y25.76%
OCF growth 5Y31.92%